Puma Historical Income Statement
| PBYI Stock | USD 5.02 0.14 2.87% |
Historical analysis of Puma Biotechnology income statement accounts such as EBITDA of 47 M, Total Operating Expenses of 153.3 M, Income Before Tax of 23.8 M or Net Income of 22.7 M can show how well Puma Biotechnology performed in making a profits. Evaluating Puma Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Puma Biotechnology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Puma Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Puma Biotechnology is a good buy for the upcoming year.
Puma |
About Puma Income Statement Analysis
Puma Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Puma Biotechnology shareholders. The income statement also shows Puma investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Puma Biotechnology Income Statement Chart
Puma Biotechnology Income Statement is one of the three primary financial statements used for reporting Puma's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Puma Biotechnology revenue and expense. Puma Biotechnology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Puma Biotechnology's EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Total Operating Expenses is estimated to increase to about 153.3 M, while Other Operating Expenses is projected to decrease to under 174.6 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Puma Biotechnology. It is also known as Puma Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Puma Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Puma Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.As of now, Puma Biotechnology's EBITDA is increasing as compared to previous years. The Puma Biotechnology's current Total Operating Expenses is estimated to increase to about 153.3 M, while Other Operating Expenses is projected to decrease to under 174.6 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 10.6M | 8.9M | 10.2M | 9.1M | Interest Income | 160K | 813K | 2.4M | 1.5M |
Puma Biotechnology income statement Correlations
Click cells to compare fundamentals
Puma Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Puma Biotechnology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 15M | 14.1M | 12.8M | 11.5M | 13.3M | 14.0M | |
| Other Operating Expenses | 311.4M | 255.5M | 251.9M | 197.3M | 202.4M | 174.6M | |
| Operating Income | (39.1M) | (30.4M) | (8.9M) | 23.7M | 33.3M | 34.9M | |
| Ebit | (39.1M) | (30.4M) | (8.9M) | 23.7M | 33.3M | 34.9M | |
| Ebitda | (36.1M) | (29.5M) | 1.7M | 31.5M | 44.8M | 47.0M | |
| Total Operating Expenses | 274.6M | 216.1M | 188.2M | 142.2M | 139.7M | 153.3M | |
| Income Before Tax | (75.6M) | (59.8M) | (28.8M) | 500K | 22.7M | 23.8M | |
| Net Income | (82.7M) | (60M) | (29.1M) | 912K | 21.6M | 22.7M | |
| Selling General Administrative | 140.5M | 118.5M | 116.3M | 90.0M | 88.4M | 65.7M | |
| Depreciation And Amortization | 3M | 900K | 10.6M | 7.8M | 11.5M | 12.1M | |
| Total Revenue | 272.3M | 225.1M | 253.2M | 228M | 235.6M | 126.3M | |
| Gross Profit | 235.5M | 185.7M | 189.5M | 172.9M | 173.0M | 101.1M | |
| Net Income From Continuing Ops | (75.6M) | (60.0M) | (29.1M) | 2K | 3.7M | 3.9M | |
| Research Development | 132.9M | 97.7M | 71.9M | 52.2M | 50.4M | 47.9M | |
| Cost Of Revenue | 36.8M | 39.4M | 63.7M | 55.1M | 62.7M | 65.8M | |
| Non Operating Income Net Other | (21.5M) | (15.3M) | (17.3M) | (11.7M) | (10.5M) | (10.0M) | |
| Total Other Income Expense Net | (36.5M) | (29.4M) | (19.9M) | (23.2M) | (10.6M) | (11.1M) | |
| Net Income Applicable To Common Shares | (75.6M) | (60.0M) | (29.1M) | 2K | 2.3K | 2.4K | |
| Income Tax Expense | 7.1M | 200K | 300K | 500K | 1.1M | 1.1M | |
| Net Interest Income | (12.2M) | (13.6M) | (12.6M) | (10.8M) | (10.9M) | (11.4M) | |
| Interest Income | 2.8M | 500K | 160K | 813K | 2.4M | 1.5M | |
| Reconciled Depreciation | 8.1M | 10.0M | 10.6M | 8.9M | 10.2M | 9.1M | |
| Selling And Marketing Expenses | 1.2M | 88K | 6K | 22K | 881K | 925.1K |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Puma Biotechnology using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Puma Biotechnology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more detail on how to invest in Puma Stock please use our How to Invest in Puma Biotechnology guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |
Is Puma Biotechnology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Puma Biotechnology. If investors know Puma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Puma Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.78) | Earnings Share 0.45 | Revenue Per Share 4.999 | Quarterly Revenue Growth 0.099 | Return On Assets 0.0919 |
The market value of Puma Biotechnology is measured differently than its book value, which is the value of Puma that is recorded on the company's balance sheet. Investors also form their own opinion of Puma Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is Puma Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Puma Biotechnology's market value can be influenced by many factors that don't directly affect Puma Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Puma Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Puma Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Puma Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.